-
Mashup Score: 2
Bolt Biotherapeutics shares fell 37% after shelving its lead candidate, pivoting its pipeline, halving its staff, and upending its C-suite.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 10New Chemotherapy-Induced Cancer Cell Suicide Pathway Uncovered - 14 hour(s) ago
Discovery of SLFN11 as the strongest biomarker for chemotherapy responsiveness suggests relevance for ribosomal stalling in the effectiveness of cancer therapy
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 21AlphaFold2 Shows Utility in Drug Discovery through Ligand Discovery - 18 hour(s) ago
AlphaFold2 is an AI system that predicts the 3D structures of proteins and can be used to help identify a multitude of drug candidates.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 10Online Event - 18 hour(s) ago
About five million people in the United States alone live with traumatic brain injuries (TBIs). These injuries can quadruple the risk of developing Alzheimer’s disease, and other dementias, and increase the likelihood of developing neurodegenerative diseases such as amyotrophic lateral sclerosis. Rodent models of TBI have clarified some aspects of these injuries; however, most treatment approaches have had limited success because some of the details of the underlying mechanisms are still unclear. In this
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 22Engineered Gene Delivery Vehicle Crosses Blood-Brain Barrier in Mice - 19 hour(s) ago
Researchers from the Broad Institute of MIT and Harvard report they have engineered a gene delivery vehicle that uses a human protein to efficiently cross the blood-brain barrier and deliver a disease-relevant gene to the brain in mice.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 11Online Event - 2 day(s) ago
While humanized animalmodels are relatively new to drug development compared to their non-humanizedcounterparts, they are critical tools in the landscape of biologic drugdevelopment. Their success is due to the ability of humanized models to developersrefine their therapies to boost efficacy and reduce toxicity which is crucialfor advancing them to the clinic. In this GEN webinar, Aaron Rose, PhD, explores how biological therapeutics are reshaping the traditional drug development process and why humanized
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 9
Circe Biosciences entered into an exclusive worldwide licensing agreement arranged by Harvard’s Office of Technology Development (OTD).
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 2Online Event - 2 day(s) ago
Altered dopaminergic neurotransmission underlies a variety of neurological and neuropsychiatric diseases, including playing a central role in the neurodegenerative processes that lead to Parkinson’s disease. Loss of dopaminergic neurons in the substantia nigra within the brain disrupts motor control pathways resulting in the development and progression of symptoms such as bradykinesia, rigidity, and tremors. The degeneration of dopamine neurons is believed to result from neuronal dysregulation and cell
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 21Rapidly Aging Brain Cells Discovered Through Single-Cell Mapping in Alzheimer’s Disease - 2 day(s) ago
A new study shows some brain cells age faster than others in Alzheimer’s cases, and there are sex-specific differences in the aging process.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 32Exercise Promotes Neurogenesis in the Aging Mouse Brain - 3 day(s) ago
Researchers were surprised and excited about the extent to which exercise rejuvenates and transforms the composition of immune cells within the brain
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet
StockWatch: Like a Bolt from the Blue, Cancer Drug Developer Nosedives Bolt Biotherapeutics shares fell 37% after shelving its lead candidate, pivoting its pipeline, halving its staff, and upending its C-suite. Learn more: https://t.co/ZwCOOoIgyX https://t.co/FECukFE5Aa